Here are four things to know:
1. The study will test the ALLOB, the company’s allogeneic bone-cell therapy product.
2. Bone Therapeutics anticipates having efficacy and safety data for the 32 patients by mid-2019.
3. The study will follow the patients for 12 months.
4. The interim results of the study revealed bone formation and pain improvement in patients with ALLOB.
More articles on biologics:
Positive clinical trial results for human dermal fibroblast injection CybroCell: 7 key insights
Stempeutics Research inks deal with Alkem Laboratories for osteoarthritis drug: 3 insights
Bioventus to be sole US distributor of Supartz Fx through May 2028 — 3 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
